First American Trust, Fsb Sage Therapeutics, Inc. Transaction History

First American Trust, Fsb

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 28, 2020	SELL	$26.15 - $77.24 $498,942 - $1.47 Million	-19,080 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$60.18 - $154.77 $20,521 - $52,776	341 Added 1.82%	19,080 $1.38 Million
Q3 2019 Oct 10, 2019	BUY	$140.29 - $189.96 $124,156 - $168,114	885 Added 4.96%	18,739 $2.63 Million
Q2 2019 Jul 08, 2019	BUY	$157.85 - $183.09 $66,139 - $76,714	419 Added 2.4%	17,854 $3.27 Million
Q1 2019 Apr 09, 2019	BUY	$89.33 - $163.65 $68,962 - $126,337	772 Added 4.63%	17,435 $2.77 Million
Q4 2018 Jan 11, 2019	BUY	$81.94 - $139.71 $1.37 Million - $2.33 Million	16,663 New	16,663 $1.6 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of First American Trust, Fsb, based on Form 13F filings with the SEC.

Stay updated on First American Trust, Fsb with notifications on news.